Investigational drug · Phase 2
JS111
Also called: AP-L1898
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NSCLC.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "JS111"
First trial start
2025
Apr 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JS111", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "JS111" as an intervention, largest first.
- JS111 in Patients With Advanced NSCLC Harboring EGFR MutationsActive, not recruiting
Suzhou Junjing BioSciences Co., Ltd.Industry
NCT06940401 · 44 participants · Start Apr 30, 2025 · Primary completion Jul 30, 2028
Drug: JS111 capsules (AP-L1898) · For: NSCLC
Sites: Shanghai, China
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07518160 · 35 participants (planned) · Start Apr 21, 2026 · Primary completion Apr 23, 2028
Drug: JS212 for Injection+JS111 capsules (AP-L1898) · For: Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Sites: Shanghai, China · 2 sites in all
Suzhou Junjing BioSciences Co., Ltd.Industry
NCT04993391 · 32 participants · Start Jul 14, 2021 · Primary completion Feb 4, 2024
Drug: JS111(AP-L1898 Capsules); JS111(AP-L1898 Capsules) and 3 more · For: Lung Cancer
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 37 sites in all
- JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLCNot yet recruiting
Huan ZhouAcademic, hospital or other
NCT07714304 · 20 participants (planned) · Start Jul 13, 2026 · Primary completion Nov 13, 2026
Drug: JS212 for Injection; JS111 capsules (AP-L1898) · For: NSCLC Harboring EGFR Mutations
Sites: Hefei, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Antigenicity and genetic properties of an Eurasian avian-like H1N1 swine influenza virus in Jiangsu Province, China.
He F, Yu H, Liu L, et al. · Biosaf Health 2024
- A plant-inducible gene of Xanthomonas campestris pv. campestris encodes an exocellular component required for growth in the host and hypersensitivity on nonhosts.
Kamoun S, Kado CI · J Bacteriol 1990
Also in development for NSCLC
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FurmonertinibPhase 38 trials
Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.